ERBB2 and cancer: Similarly, Fu Z et al. found the risk of fatal TRAEs with HER2-targeted ADCs to be 0.78% (95% CI [0.0028, 0.0137]) compared to standard control treatments in cancer patients (Fu et al., 2023).